Amniotic Membrane Mesenchymal Cells-Derived Factors Skew T Cell Polarization Toward Treg and Downregulate Th1 and Th17 Cells Subsets

Stem Cell Reviews and Reports

Volumn 11, Issue 3, 2015, Pages 394-407

  Pianta, Stefano ^a,b   Bonassi Signoroni, Patrizia ^a   Muradore, Ivan ^a   Rodrigues, Melissa Francis ^a   Rossi, Daniele ^a   Silini, Antonietta ^a   Parolini, Ornella ^a  

^a Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Conditioned medium; Cytokines; Human amniotic membrane mesenchymal cells; Human placenta; Immunomodulation; Mesenchymal stromal cells; Secretome; T cells; Th1; Th17; Th2; Treg

Indexed keywords

CONDITIONED MEDIUM; TRANSFORMING GROWTH FACTOR BETA;

AMNION; CELL DIFFERENTIATION; CELL POLARITY; CHEMISTRY; COCULTURE; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL;

AMNION; CELL DIFFERENTIATION; CELL POLARITY; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; HUMANS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84930380040     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9558-4     Document Type: Article

References (69)

1. Cetrulo, K. J., Cetrulo, C. L., Jr., & Taghizadeh, R. R. (Eds.). (2013). Perinatal stem cells. Hoboken: Wiley.
2. Anzalone, R., Iacono Lo, M., Loria, T., Di Stefano, A., Giannuzzi, P., Farina, F., & La Rocca, G. (2011). Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Reviews and Reports, 7(2), 342–363. doi:10.1007/s12015-010-9196-4.
3. La Rocca, G., Corrao, S., Iacono Lo, M., Corsello, T., Farina, F., & Anzalone, R. (2012). Novel immunomodulatory markers expressed by human WJ-MSC: an updated review in regenerative and reparative medicine. The Open Tissue Engineering and Regenerative Medicine Journal, 5, 50–58.
4. La Rocca, G., Iacono Lo, M., Corsello, T., Corrao, S., Farina, F., & Anzalone, R. (2013). Human Wharton’s jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Current Stem Cell Research & Therapy, 8(1), 100–113.
5. Moodley, Y., Vaghjiani, V., Chan, J., Baltic, S., Ryan, M., Tchongue, J., et al. (2013). Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS ONE, 8(8), e69299. doi:10.1371/journal.pone.0069299.
6. Parolini, O., Souza-Moreira, L., O’Valle, F., Magatti, M., Hernandez-Cortes, P., Gonzalez-Rey, E., & Delgado, M. (2014). Therapeutic effect of human amniotic membrane-derived cells on experimental arthritis and other inflammatory disorders. Arthritis & Rheumatology, 66(2), 327–339. doi:10.1002/art.38206.
7. Parolini, O., Alviano, F., Bergwerf, I., Boraschi, D., De Bari, C., De Waele, P., et al. (2010, February). Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells and Development, 19(2), 143–154. doi:10.1089/scd.2009.0404.
8. Manuelpillai, U., Moodley, Y., Borlongan, C. V., & Parolini, O. (2011). Amniotic membrane and amniotic cells: potential therapeutic tools to combat tissue inflammation and fibrosis? Placenta, 32(Suppl 4), S320–S325. doi:10.1016/j.placenta.2011.04.010.
9. Silini, A., Parolini, O., Huppertz, B., & Lang, I. (2013). Soluble factors of amnion-derived cells in treatment of inflammatory and fibrotic pathologies. Current Stem Cell Research & Therapy, 8(1), 6–14.
10. Parolini, O., Alviano, F., Bagnara, G. P., Bilic, G., Bühring, H.-J., Evangelista, M., et al. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells. Stem Cells, 26(2), 300–311. doi:10.1634/stemcells.2007-0594.
11. Parolini, O., & Caruso, M. (2011). Review: Preclinical studies on placenta-derived cells and amniotic membrane: an update. Placenta, 32(Suppl 2), S186–S195. doi:10.1016/j.placenta.2010.12.016.
12. Pozzobon, M., Piccoli, M., & De Coppi, P. (2014). Stem cells from fetal membranes and amniotic fluid: markers for cell isolation and therapy. Cell and Tissue Banking, 15(2), 199–211. doi:10.1007/s10561-014-9428-y.
13. Bailo, M., Soncini, M., Vertua, E., Signoroni, P. B., Sanzone, S., Lombardi, G., et al. (2004). Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation, 78(10), 1439–1448.
14. Magatti, M., De Munari, S., Vertua, E., Gibelli, L., Wengler, G. S., & Parolini, O. (2008). Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells, 26(1), 182–192. doi:10.1634/stemcells.2007-0491.
15. Wolbank, S., Peterbauer, A., Fahrner, M., Hennerbichler, S., van Griensven, M., Stadler, G., et al. (2007). Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Engineering, 13(6), 1173–1183. doi:10.1089/ten.2006.0313.
16. Banas, R. A., Trumpower, C., Bentlejewski, C., Marshall, V., Sing, G., & Zeevi, A. (2008). Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Human Immunology, 69(6), 321–328. doi:10.1016/j.humimm.2008.04.007.
17. Manochantr, S., U-pratya, Y., Kheolamai, P., Rojphisan, S., Chayosumrit, M., Tantrawatpan, C., et al. (2013). Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton’s jelly and umbilical cord. Internal Medicine Journal, 43(4), 430–439. doi:10.1111/imj.12044.
18. Magatti, M., De Munari, S., Vertua, E., Nassauto, C., Albertini, A., Wengler, G. S., & Parolini, O. (2009). Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplantation, 18(8), 899–914. doi:10.3727/096368909X471314.
19. Banas, R. A., Miller, C., Guzik, L., & Zeevi, A. (2013). Amnion-derived multipotent progenitor cells inhibit blood monocyte differentiation into mature dendritic cells. Cell Transplantation. doi:10.3727/096368913X670165.
20. Cargnoni, A., Gibelli, L., Tosini, A., Signoroni, P. B., Nassuato, C., Arienti, D., et al. (2009). Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplantation, 18(4), 405–422. doi:10.3727/096368909788809857.
21. Ohshima, M., Yamahara, K., Ishikane, S., Harada, K., Tsuda, H., Otani, K., et al. (2012). Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis. Journal of Molecular and Cellular Cardiology, 53(3), 420–428. doi:10.1016/j.yjmcc.2012.06.020.
22. Sant’Anna, L. B., Cargnoni, A., Ressel, L., Vanosi, G., & Parolini, O. (2011). Amniotic membrane application reduces liver fibrosis in a bile duct ligation rat model. Cell Transplantation, 20(3), 441–453. doi:10.3727/096368910X522252.
23. Ricci, E., Vanosi, G., Lindenmair, A., Hennerbichler, S., Peterbauer-Scherb, A., Wolbank, S., et al. (2013). Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model. Cell and Tissue Banking, 14(3), 475–488. doi:10.1007/s10561-012-9337-x.
24. Cargnoni, A., Di Marcello, M., Campagnol, M., Nassuato, C., Albertini, A., & Parolini, O. (2009). Amniotic membrane patching promotes ischemic rat heart repair. Cell Transplantation, 18(10), 1147–1159. doi:10.3727/096368909X12483162196764.
25. Cargnoni, A., Ressel, L., Rossi, D., Poli, A., Arienti, D., Lombardi, G., & Parolini, O. (2012). Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis. Cytotherapy, 14(2), 153–161. doi:10.3109/14653249.2011.613930.
26. Cargnoni, A., Piccinelli, E. C., Ressel, L., Rossi, D., Magatti, M., Toschi, I., et al. (2014). Conditioned medium from amniotic membrane-derived cells prevents lung fibrosis and preserves blood gas exchanges in bleomycin-injured mice-specificity of the effects and insights into possible mechanisms. Cytotherapy, 16(1), 17–32. doi:10.1016/j.jcyt.2013.07.002.
27. Rossi, D., Pianta, S., Magatti, M., Sedlmayr, P., & Parolini, O. (2012). Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as Key effectors of its immunomodulatory activity. PLoS ONE, 7(10), e46956–14. doi:10.1371/journal.pone.0046956.
28. Magatti, M., Caruso, M., De Munari, S., Vertua, E., De, D., Manuelpillai, U., & Parolini, O. (2014). Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocyte-derived dendritic cell differentiation and function. Cell Transplantation. doi:10.3727/096368914X684033.
29. Abumaree, M. H., Jumah, M. A., Kalionis, B., Jawdat, D., Khaldi, A., Abomaray, F. M., et al. (2013). Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Reviews and Reports, 9(5), 620–641. doi:10.1007/s12015-013-9455-2.
30. Singer, N. G., & Caplan, A. I. (2011). Mesenchymal stem cells: mechanisms of inflammation. Annual Review of Pathology, 6(1), 457–478. doi:10.1146/annurev-pathol-011110-130230.
31. Law, S., & Chaudhuri, S. (2013). Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges. American Journal of Stem Cells, 2(1), 22–38.
32. Lim, J. H., Kim, J. S., Yoon, I. H., Shin, J. S., Nam, H. Y., Yang, S. H., et al. (2010). Immunomodulation of delayed-type hypersensitivity responses by mesenchymal stem cells is associated with bystander T cell apoptosis in the draining lymph node. The Journal of Immunology, 185(7), 4022–4029. doi:10.4049/jimmunol.0902723.
33. González, M. A., Gonzalez-Rey, E., Rico, L., Büscher, D., & Delgado, M. (2009). Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology, 136(3), 978–989. doi:10.1053/j.gastro.2008.11.041.
34. Boumaza, I., Srinivasan, S., Witt, W. T., Feghali-Bostwick, C., Dai, Y., Garcia-Ocana, A., & Feili-Hariri, M. (2009). Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. Journal of Autoimmunity, 32(1), 33–42. doi:10.1016/j.jaut.2008.10.004.
35. Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annual Review of Immunology, 22, 745–763. doi:10.1146/annurev.immunol.22.012703.104702
36. Filaci, G., Fenoglio, D., Fravega, M., Ansaldo, G., Borgonovo, G., Traverso, P., et al. (2007). CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. Journal of Immunology, 179(7), 4323–4334. doi:10.4049/jimmunol.179.7.4323.
37. Uccelli, A., Moretta, L., & Pistoia, V. (2008). Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 8(9), 726–736. doi:10.1038/nri2395.
38. Jones, S., Horwood, N., Cope, A., & Dazzi, F. (2007). The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. Journal of Immunology, 179(5), 2824–2831.
39. Kavanagh, D. P. J., Robinson, J., & Kalia, N. (2014). Mesenchymal stem cell priming: fine-tuning adhesion and function. Stem Cell Reviews, 10(4), 587–599. doi:10.1007/s12015-014-9510-7.
40. Pevsner-Fischer, M., Levin, S., & Zipori, D. (2011). The origins of mesenchymal stromal cell heterogeneity. Stem Cell Reviews and Reports, 7(3), 560–568. doi:10.1007/s12015-011-9229-7.
41. Kronsteiner, B., Peterbauer-Scherb, A., Grillari-Voglauer, R., Redl, H., Gabriel, C., van Griensven, M., & Wolbank, S. (2011). Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cellular Immunology, 267(1), 30–38. doi:10.1016/j.cellimm.2010.11.001.
42. Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014). IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. The Journal of Immunology, 192(4), 1491–1501. doi:10.4049/jimmunol.1301828.
43. Sivanathan, K. N., Gronthos, S., Rojas-Canales, D., Thierry, B., & Coates, P. T. (2014). Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Reviews and Reports, 10(3), 351–375. doi:10.1007/s12015-014-9495-2
44. Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E., & Dazzi, F. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101(9), 3722–3729. doi:10.1182/blood-2002-07-2104.
45. Filaci, G., Fravega, M., Fenoglio, D., Rizzi, M., Negrini, S., Viggiani, R., & Indiveri, F. (2004). Non-antigen specific CD8+ T suppressor lymphocytes. Clinical and Experimental Medicine, 4(2), 86–92. doi:10.1007/s10238-004-0042-3.
46. Filaci, G., Fenoglio, D., & Indiveri, F. (2011). CD8(+) T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity, 44(1), 51–57. doi:10.3109/08916931003782171.
47. Najafian, N., Chitnis, T., Salama, A. D., Zhu, B., Benou, C., Yuan, X., et al. (2003). Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. The Journal of Clinical Investigation, 112(7), 1037–1048. doi:10.1172/JCI17935.
48. Cortesini, R., LeMaoult, J., Ciubotariu, R., & Cortesini, N. S. (2001). CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunological Reviews, 182, 201–206.
49. Filaci, G., Fravega, M., Negrini, S., Procopio, F., Fenoglio, D., Rizzi, M., et al. (2004). Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Human Immunology, 65(2), 142–156. doi:10.1016/j.humimm.2003.12.001.
50. Engela, A. U., Baan, C. C., Litjens, N. H. R., Franquesa, M., Betjes, M. G. H., Weimar, W., & Hoogduijn, M. J. (2013). Mesenchymal stem cells control alloreactive CD8 +CD28 −T cells. Clinical and Experimental Immunology, 174(3), 449–458. doi:10.1111/cei.12199.
51. Weng, J., He, C., Lai, P., Luo, C., Guo, R., Wu, S., et al. (2012). Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Molecular Therapy, 20(12), 2347–2354. doi:10.1038/mt.2012.208.
52. Chaudhry, A., & Rudensky, A. Y. (2013). Control of inflammation by integration of environmental cues by regulatory T cells. The Journal of Clinical Investigation, 123(3), 939–944. doi:10.1172/JCI57175.
53. Elkord, E. (2014). Thymus-derived, peripherally-derived and in vitro-induced T regulatory cells. Frontiers in Immunology, 5, 17. doi:10.3389/fimmu.2014.00017.
54. Ghannam, S., Pène, J., Moquet-Torcy, G., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. The Journal of Immunology, 185(1), 302–312. doi:10.4049/jimmunol.0902007.
55. Zuo, D., Liu, X., Shou, Z., Fan, H., Tang, Q., Duan, X., et al. (2013). Study on the interactions between transplanted bone marrow-derived mesenchymal stem cells and regulatory T cells for the treatment of experimental colitis. International Journal of Molecular Medicine, 32(6), 1337–1344. doi:10.3892/ijmm.2013.1529.
56. Gonzalez-Rey, E., González, M. A., Varela, N., O’Valle, F., Hernandez-Cortes, P., Rico, L., et al. (2009). Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(01), 241–248. doi:10.1136/ard.2008.101881.
57. Ivanova-Todorova, E., Bochev, I., Dimitrov, R., Belemezova, K., Mourdjeva, M., Kyurkchiev, S., et al. (2012). Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4+FOXP3+ cells and increases IL-10 secretion. Journal of Biomedicine and Biotechnology, 2012(1), 1–8. doi:10.1111/j.1600-0897.2009.00707.x.
58. Curotto de Lafaille, M. A., & Lafaille, J. J. (2009). Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity, 30(5), 626–635. doi:10.1016/j.immuni.2009.05.002.
59. Tiemessen, M. M., Jagger, A. L., Evans, H. G., van Herwijnen, M. J. C., John, S., & Taams, L. S. (2007). CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proceedings of the National Academy of Sciences, 104(49), 19446–19451. doi:10.1073/pnas.0706832104.
60. Ochoa-Reparaz, J., Rynda, A., Ascon, M. A., Yang, X., Kochetkova, I., Riccardi, C., et al. (2008). IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. Journal of Immunology, 181(2), 954–968. doi:10.4049/jimmunol.181.2.954.
61. Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., et al. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 110(4), 1225–1232. doi:10.1182/blood-2006-12-064527.
62. Moncrieffe, H., Nistala, K., Kamhieh, Y., Evans, J., Eddaoudi, A., Eaton, S., & Wedderburn, L. R. (2010). High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. The Journal of Immunology, 185(1), 134–143. doi:10.4049/jimmunol.0803474.
63. Dwyer, K. M., Hanidziar, D., Putheti, P., Hill, P. A., Pommey, S., McRae, J. L., et al. (2010). Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. American Journal of Transplantation, 10(11), 2410–2420. doi:10.1111/j.1600-6143.2010.03291.x.
64. Wang, R., Kozhaya, L., Mercer, F., Khaitan, A., Fujii, H., & Unutmaz, D. (2009). Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proceedings of the National Academy of Sciences, 106(32), 13439–13444. doi:10.1073/pnas.0901965106.
65. Moseman, E. A., Liang, X., Dawson, A. J., Panoskaltsis-Mortari, A., Krieg, A. M., Liu, Y. J., et al. (2004). Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. Journal of Immunology, 173(7), 4433–4442. doi:10.4049/jimmunol.173.7.4433.
66. Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., et al. (2006). Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. Journal of Immunology, 177(7), 4376–4383. doi:10.4049/jimmunol.177.7.4376.
67. Liao, G., Detre, C., Berger, S. B., Engel, P., de Waal Malefyt, R., Herzog, R. W., et al. (2012). lucocorticoid-induced tumor necrosis factor receptor family-related protein regulates CD4(+)T cell-mediated colitis in mice. Gastroenterology, 142(3), 582–591. doi:10.1053/j.gastro.2011.11.031.
68. Shi, Y., Su, J., Roberts, A. I., Shou, P., Rabson, A. B., & Ren, G. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends in Immunology, 33(3), 136–143. doi:10.1016/j.it.2011.11.004.
69. Ren, G., Zhao, X., Zhang, L., Zhang, J., L’Huillier, A., Ling, W., et al. (2010). Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells Are critical for immunosuppression. Journal of Immunology, 184(5), 2321–2328. doi:10.4049/jimmunol.0902023.